The PCSK9 inhibitors are recommended for secondary prevention of MACE in patients with and without diabetes based on 15% RRR for cardiovascular death, MI, or stroke, as well as significant RRR in each component of the MACE composite, in separate trials.67,68. Here, PCSK9 is linked to diabetes mellitus.